ReviewFrontiers in cardiovascular medicine2020
MiR-223-3p in Cardiovascular Diseases: A Biomarker and Potential Therapeutic Target.
Review in Frontiers in cardiovascular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Lower Plasma miR-223 Level Is Associated with Clopidogrel Resistance in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.Journal of interventional cardiology · 2023Pooled it
- Scoping review on the relationship between microRNAs (miRNAs) and short sleep disorder or insomnia with short sleep duration.Sleep medicine: X · 2026Article
- The Wound-Heart Axis: Can Chronic Wounds Contribute to Cardiac Dysfunction?International journal of molecular sciences · 2026Review
- RNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis.Science advances · 2026Article
- Ion channel and biophysical properties of extracellular vesicles.The Journal of biological chemistry · 2026Review
- miR-128-3p and miR-223-3p as Potential Biomarkers of Metabolic Dysfunction in Liver Tissue from Patients Undergoing Metabolic Bariatric Surgery.Obesity surgery · 2026Article
- Exploration of the expression and regulatory mechanisms of platelet miR-223-3p in hand, foot, and mouth disease (HFMD) complicated by encephalitis.Translational pediatrics · 2026Article
- Dynamic microRNA Signatures as Biomarkers for Cardiac Ischemia and Remodeling.International journal of molecular sciences · 2026Article
- Functional Role and Diagnostic Potential of Biomarkers in the Early Detection of Mastitis in Dairy Cows.Animals : an open access journal from MDPI · 2026Review
- miR-223-3p predicts prognosis of hepatitis B virus-related acute-on-chronic liver failure and is involved in hepatocyte injury via HSP90B1.Hereditas · 2025Article
- Circular RNAs in Cardiovascular Disease: Mechanisms, Biomarkers, and Therapeutic Frontiers.Biomolecules · 2025Review
- miRNA-Orchestrated Fibroinflammatory Responses in Heart Failure with Preserved Ejection Fraction: Translational Opportunities for Precision Medicine.Diagnostics (Basel, Switzerland) · 2025Review
- New biomarkers of inflammation associated with haemodialysis.Clinical kidney journal · 2025Article
- Epigenetic Mechanisms in Heart Diseases.Reviews in cardiovascular medicine · 2025Review
- Utilizing Circulating MicroRNAs for Personalized Exercise Programs: Insights into Physiological Adaptations and Individual Responses.Iranian journal of biotechnology · 2025Review
- Global Perspectives on Coronary Artery Disease: The Emerging Role of miRNAs.Current atherosclerosis reports · 2025Review
- A Multiscale In Silico Analysis Identifies Plasma Levels of miR-223-3p as an Emerging Biomarker of Cardiac Response to Acute Exercise and Training in Olympic Medallists.Scandinavian journal of medicine & science in sports · 2025Article
- Plasma extracellular vesicle cargo microRNAs are associated with heart failure and cardiovascular death following acute coronary syndrome.Extracellular vesicle · 2025Article
- Identification of novel therapeutic targets in hepatitis-B virus-associated membranous nephropathy using scRNA-seq and machine learning.Scientific reports · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases, involving vasculopathy, cardiac dysfunction, or circulatory disturbance, have become the major cause of death globally and brought heavy social burdens. The complexity and diversity of the pathogenic factors add difficulties to diagnosis and treatment, as well as lead to poor prognosis of these diseases. MicroRNAs are short non-coding RNAs to modulate gene expression through directly binding to the 3'-untranslated regions of mRNAs of target genes and thereby to downregulate the protein levels post-transcriptionally. The multiple regulatory effects of microRNAs have been investigated extensively in cardiovascular diseases. MiR-223-3p, expressed in multiple cells such as macrophages, platelets, hepatocytes, and cardiomyocytes to modulate their cellular activities through targeting a variety of genes, is involved in the pathological progression of many cardiovascular diseases. It participates in regulation of several crucial signaling pathways such as phosphatidylinositol 3-kinase/protein kinase B, insulin-like growth factor 1, nuclear factor kappa B, mitogen-activated protein kinase, NOD-like receptor family pyrin domain containing 3 inflammasome, and ribosomal protein S6 kinase B1/hypoxia inducible factor 1 α pathways to affect cell proliferation, migration, apoptosis, hypertrophy, and polarization, as well as electrophysiology, resulting in dysfunction of cardiovascular system. Here, in this review, we will discuss the role of miR-223-3p in cardiovascular diseases, involving its verified targets, influenced signaling pathways, and regulation of cell function. In addition, the potential of miR-223-3p as therapeutic target and biomarker for diagnosis and prediction of cardiovascular diseases will be further discussed, providing clues for clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.